Lack of specificity of cyclosporine immunoassays: Results of a College of American Pathologists study

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 1, 2003, Pages 19-22

  Soldin, Steven J ^a,b,g   Steele, Bernard W ^c   Witte, David L ^d   Wang, Edward ^e   Elin, Ronald J ^f  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Collaborative Laboratory Services ^*  (United States)

^e Molecular Pathology Division   (United States)

^f University of Louisville School of Medicine   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DRUG METABOLITE;

ARTICLE; CROSS REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; STEADY STATE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS REACTIONS; CYCLOSPORINE; IMMUNOASSAY; LABORATORIES; LYMPHOCYTE CULTURE TEST, MIXED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 0037280547     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Soldin SJ, Papanastasiou-Diamandis A, Heyes J, et al. Are immunoassays for digoxin reliable? Clin Biochem. 1984;17:317-320.
2. Shen S, Elin RJ, Soldin SJ. Characterization of cross-reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. Clin Biochem. 2001;34:157-158.
3. Holt DW, Johnston A. Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit. 1995;17:625-630.
4. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
5. Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring report of the Task Force on Cyclosporine Monitoring. Clin Chem. 1987;33:1269-1288.
6. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem. 1990;36:1841-1846.
7. Kahan BD, Shaw LM, Holt DW, et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem. 1990;36:1510-1516.
8. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit. 1995;17:631-637.
9. Soldin OP, Soldin SJ. Review: therapeutic drug monitoring in pediatrics. Ther Drug Monit. 2002;24:1-8.
10. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Ther Drug Monit. 2002;24:59-67.
11. Schutz E, Svinarov D, Shipkova M, et al. Cyclosporine whole blood immunoassays (AxSYM, CEDIA, and EMIT): a critical overview of performance characteristics and comparison with HPLC. Clin Chem. 1998;44:2158-2164.
12. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem. 1999;45:371-381.
13. Murthy JN, Yatscoff RW, Soldin SJ. Cyclosporine metabolite cross: reactivity in different cyclosporine assays. Clin Biochem. 1998;31:159-163.
14. Soldin SJ. Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Clin Biochem. 1998;31:381-384.
15. LeGatt DF, Coates JE, Simpson AI, et al. A comparison of cyclosporine assays using sequential samples from selected transplant patients. Clin Biochem. 1994;27:43-48.
16. Kolars JC, Awni WN, Merion RM, et al. First pass metabolism of cyclosporine by the gut. Lancet. 1991;338:1488-1490.
17. Vickers AEM, Fischer V, Connors S, et al. Cyclosporine A metabolism in human liver, kidney and intestine slices: comparison to rat and dog slices and human cell lines. Drug Metab Dispos. 1992;20:802-809.
18. Christians U, Sewing K. Cyclosporine metabolism in liver transplant patients. Pharmacol Ther. 1993;57:291-345.
19. Wenger RM. Structures of cyclosporine and its metabolites. Transplant Proc. 1990;22:1104-1108.
20. Russell R, Donnelly J, Palasynski E, et al. A preliminary study to evaluate an in vitro assay for determining patient whole blood immunosuppressive cyclosporine A and metabolite activity: comparison with cytosolic binding assays using cyclophilin or a 50 kDa binding protein, and the Abbott TDx cyclosporin A parent, and parent and metabolites assays. Ther Drug Monit. 1991;13:32-36.
21. Soldin SJ. Receptor (immunophilin-binding) assay for immunosuppressive drugs. Ther Drug Monit. 1995;17:574-576.
22. Rosano T, Freed B, Cerill J. Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation. 1986;42:262-267.
23. Copeland KR, Yatscoff RW, McKenna RM. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectrometry and nuclear magnetic resonance. Clin Chem. 1990;36:225-229.
24. Copeland KR, Yatscoff RW, McKenna RM. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem. 1990;36:225-229.
25. Copeland KR, Yatscoff RW. Immunosuppressive activity and toxicity of cyclosporine metabolites characterized by mass spectroscopy and nuclear magnetic resonance. Transplant Proc. 1990;22:1146-1149.
26. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2001;34:285-290.
27. Morris RG, Lam AK. Cyclosporine monitoring in Australia: survey of laboratory practices in 2000. Ther Drug Monit. 2002;24:471-478.
28. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor Neoral therapy? Ther Drug Monit. 2002; 24:40-46.
29. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 postrenal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
30. Levy GA, Lake JR, Beauregard-Zollinger L, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine blood level monitoring based on two-hour post-dose levels. Transplantation. 2000;69:387.
31. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 1999;68:1839-1842.
32. Schutz E, Streit F, Dias VC, et al. CsA immunoassays in comparison to LCMS/MS: is there a difference between trough (C0) and C2 levels? Ther Drug Monit. 2001;23:471.
33. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem. 2000;46:872-874.